SEARCH

SEARCH BY CITATION

References

  • 1
    Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973–1999, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1973_1999/, 2002.
  • 2
    Iverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91–01. Blood 2001; 97: 121112181.
  • 3
    Cancer Statistics, 2002. Jemal A; Thomas A, Murray T, Thun M. CA Cancer J Clin 2002; 52: 2347.
  • 4
    Sawitsky A, Bloom D, German J. Chromosomal breakage and acute leukemia in congenital telangiectatic erythema and stunted growth. Ann Intern Med 1966; 65: 487495.
  • 5
    Greenberg BR, Wilson FD, Woo L, et al. Cytogenetics and granulopoietic effects of bone marrow fibroblastic cells in Fanconi's anemia. Br J Haematol 1981; 48: 8593.
  • 6
    Kelly L, Clark J, Gilliland DG. Comprehensive genotype analysis of leukemia: clinical and therapeutic implications. Cur Opin in Oncol 2002; 14: 1018.
  • 7
    Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 4784.
  • 8
    Bizzozero DJ, Johnson KG, Giocco A. Radiation-related leukemia in Hiroshima and Nagasaki 1946–1964. N Engl J Med 1966; 234: 591594.
  • 9
    Jacobs A. Benzene and leukemia. Br J Haematol 1989; 72: 119121.
  • 10
    Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986; 105: 360367.
  • 11
    Pedersen-Bjergaard J, Ersboll J, Mygind H, et al. Risk of acute nonlymphocytic leukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 1985; 103: 195200.
  • 12
    Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 16821687.
  • 13
    Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 13121320.
  • 14
    Grimwade D, Walker H, Oliver S, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Re-search Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 23222333.
  • 15
    Bloomfield CD, Lawrence C, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 41734179.
  • 16
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting – Arlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 38353849.
  • 17
    Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460462.
  • 18
    Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997; 90: 14101414.
  • 19
    Zhu YM, Das-Gupta EP, Russell NH, et al. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94: 733740.
  • 20
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 33233329.
  • 21
    Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473476.
  • 22
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813819.
  • 23
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896903.
  • 24
    Rees JK, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 12361241.
  • 25
    Lee EJ, George SL, Caligiuri M, et al. Parallel Phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol 1999; 17: 28312839.
  • 26
    Baer MR, George SL, Dodge RK, et al. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2001; 100: 12241232.
  • 27
    Vogler WR, Velez-Garcia E, Weiner RS, et al. A Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992; 10: 11031111.
  • 28
    Wiernik PH, Banks PL, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313319.
  • 29
    Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389395.
  • 30
    Rowe JM, Neuberg D, Friedenberg W, et al. A Phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients >55 years) with acute myelogenous leukemia AML): A study of the Eastern Cooperative Oncology Group E3993). Blood 1998; 92: 313a.
  • 31
    Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized Phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13: 843849.
  • 32
    Stone RM, Berg DT, George SL, et al. Post-remission therapy in older patients with de novo acute myeloid leukemia AML): A randomized trial comparing mitoxantrone/intermediate dose cytarabine with standard dose cytarabine CALGB study 8923). Blood 2001; 98: 548553.
  • 33
    Zittoun RA, Madelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217223.
  • 34
    Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adults acute myeloid leukemia. The Goupe Ouest Leucemies Aigues Myeloblastiques GOELAM). Blood 1997; 90: 29782986.
  • 35
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 16491656.
  • 36
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytoxic therapy with graft-versus-host effects. Blood 2001; 97: 33902400.
  • 37
    Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 7: 272.
  • 38
    Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized Phase III study of the European Organization for Research and Treatment of Cancer leukemia Group. J Clin Oncol 1989; 7: 12681274.
  • 39
    Sekeres MA, Stone RM, Zahrieh D, et al. Depression and expectations for cure in older adults with advanced myelodysplastic syndrome aMDS) or acute myeloid leukemia AML) receiving intensive chemotherapy IC) and non-intensive chemotherapy NIC): early results from a prospective study. Blood 2001; 98: 625a.
  • 40
    Peterson BA, George SL, Bhalla, et al. A Phase II trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed refractory acute myelogenous leukemia. Proc ASCO 1996; 15: 504a.
  • 41
    Rowe JM, Neuberg D, Friedenberg W, et al. A Phase III study of priming with yeast-derived granulocyte-macrophage colony-stimulating-factor rhuGM-CSF) for older adult patients >55 yrs) with acute myelogenous leukemia AML): A study of the Eastern Cooperative Oncology Group. Blood 1998; 92: 2799a.
  • 42
    Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients >55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group E1490). Blood 1995; 86: 457462.
  • 43
    Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 16711677.
  • 44
    Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a Phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 29522961.
  • 45
    Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques GOELAM). Blood 1998; 91: 27222730.
  • 46
    Bolam S, Hamblin T. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia. Drugs Aging 1999; 15: 451460.
  • 47
    Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled Phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 47104718.
  • 48
    Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemo-therapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 15561564.
  • 49
    Schiffer CAS, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95: 25302535.
  • 50
    Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341: 893900.
  • 51
    Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 18701875.
  • 52
    Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistant fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764771.
  • 53
    Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552558.
  • 54
    Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61: 11211129.
  • 55
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408415.
  • 56
    List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001; 98: 32123220.
  • 57
    Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of ara-C A), daunorubicin D) and etoposide E) with and without multidrug resistance MDR) modulation with PSC-833 P) in untreated adults with acute myeloid leukemia AML) <60 years: Final induction results of CALGB 9621. Proc Am Soc Hematol, http://www.abstracts-on-line.com/abstracts/, accessed February 21, 2002 abstr 1928).
  • 58
    Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372380.
  • 59
    Bross PF, Beitz J, Chen G, et al. Approval Summary: Gentuzamab Ozogamicin in relapsed acute myeloid leukemia. Clin Can Res 2001; 7: 14901496.
  • 60
    Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406413.